Frontiers in Oncology (May 2022)

High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival

  • Ardalan Mahmoodi,
  • Ardalan Mahmoodi,
  • Ahmed Shoqafi,
  • Ping Sun,
  • Vasily Giannakeas,
  • Vasily Giannakeas,
  • Cezary Cybulski,
  • Sharon Nofech-Mozes,
  • Jean-Yves Masson,
  • Sudha Sharma,
  • Sudha Sharma,
  • Amir Abbas Samani,
  • Amir Abbas Samani,
  • Srinivasan Madhusudan,
  • Steven A. Narod,
  • Steven A. Narod,
  • Steven A. Narod,
  • Mohammad R. Akbari,
  • Mohammad R. Akbari,
  • Mohammad R. Akbari

DOI
https://doi.org/10.3389/fonc.2022.877617
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundRECQL (also known as RECQ1 and RECQL1) is a gene of recent interest in breast cancer and an association between high levels of RECQL protein in breast cancer tumour cells and good survival of patients has been reported.MethodsTo validate this association, we measured the RECQL protein levels in tumours of 933 breast cancer patients using immunohistochemistry analysis and followed the patients for death from breast cancer.ResultsWomen with a level of RECQL protein above the 75th percentile had better 15-year disease-specific survival among ER-positive patients (62.5% vs. 48.7%, HR= 0.72, 95%CI= 0.52-0.98, p-value = 0.04), but not among ER- patients (48.9% vs. 48.0%, HR= 1.07, 95%CI= 0.67-1.69, p-value= 0.79). Among the ER-negative patients, high RECQL protein levels were associated with better survival among women who received tamoxifen treatment (67.0% vs. 51.5%, HR= 0.64, 95%CI= 0.41-0.99, p-value= 0.04).ConclusionRECQL might be a new predictive marker for tamoxifen treatment among ER-positive patients.

Keywords